CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM095042
035-os BibID:(WoS)000755462300001 (Scopus)85142845979
Első szerző:Blöndal, Mai
Cím:Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway and Sweden according to national ongoing registries / Mai Blöndal, Tiia Ainla, Jaan Eha, Piret Lõiveke, Toomas Marandi, Aet Saar, Gudrun Veldre, Robert Edfors, Christian Lewinter, Tomas Jernberg, Jarle Jortveit, Sigrun Halvorsen, Dávid Becker, Zoltán Csanádi, Tamas Ferenci, Péter Andréka, András Jánosi
Dátum:2022
ISSN:2058-5225 2058-1742
Megjegyzések:Aims Describe the characteristics, management and outcomes of hospitalized ST-segment elevation myocardial infarction (STEMI) patients according to national ongoing myocardial infarction registries in Estonia, Hungary, Norway, and Sweden. Methods and results Country-level aggregated data was used to study baseline characteristics, use of in-hospital procedures, medications at discharge, in-hospital complications, 30-day and 1-year mortality for all patients admitted with STEMI during 2014-2017 using data from EMIR (Estonia; n = 4584), HUMIR (Hungary; n = 23 685), NORMI (Norway; n = 12 414, data for 2013?2016), and SWEDEHEART (Sweden; n = 23 342). Estonia and Hungary had a higher proportion of women, patients with hypertension, diabetes, and peripheral artery disease compared to Norway and Sweden. Rates of reperfusion varied from 75.7% in Estonia to 84.0% in Sweden. Rates of recommendation of discharge medications were generally high and similar. However, Estonia demonstrated the lowest rates of dual antiplatelet therapy (78.1%) and statins (86.5%). Norway had the lowest rates of beta-blockers (80.5%) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (61.5%). The 30-day mortality rates ranged between 9.9% and 13.4% remaining lowest in Sweden. One-year mortality rates ranged from 14.8% in Sweden and 16.0% in Norway to 20.6% in Hungary and 21.1% in Estonia. Age-adjusted lethality rates were highest for Hungary and lowest for Sweden. Conclusion This inter-country comparison of data from four national ongoing European registries provides new insights into the risk factors, management and outcomes of patients with STEMI. There are several possible reasons for the findings, including coverage of the registries and variability of baseline-characteristics' definitions that need to be further explored.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ST-segment elevation myocardial infarction
Registry study
Real-world evidence
Mortality
Megjelenés:European Heart Journal - Quality of Care and Clinical Outcomes. - 8 : 3 (2022), p. 307-314. -
További szerzők:Ainla, Tiia Eha, Jaan Lõiveke, Piret Marandi, Toomas Saar, Aet Veldre, Gudrun Edfors, Robert Lewinter, Christian Jernberg, Tomas Jortveit, Jarle Halvorsen, Sigrun Becker Dávid Csanádi Zoltán (1960-) (kardiológus) Ferenci Tamás Andréka Péter Jánosi András
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM082817
035-os BibID:(scopus)85074386943 (wos)000493945000004
Első szerző:Jánosi András
Cím:Obstruktív koszorúér-betegség nélkül kialakuló heveny szívizominfarktus (MINOCA) - gyakoriság és prognózis / Jánosi András, Ferenci Tamás, Kőszegi Zsolt, Nagy Gergely György, Jambrik Zoltán, Ruzsa Zoltán, Lupkovics Géza, Csanádi Zoltán, Becker Dávid, Merkely Béla, Andréka Péter
Dátum:2019
ISSN:0030-6002 1788-6120
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban
folyóiratcikk
Megjelenés:Orvosi Hetilap. - 160 : 45 (2019), p. 1791-1797. -
További szerzők:Ferenci Tamás Kőszegi Zsolt (1962-) (kardiológus, belgyógyász) Nagy Gergely György (1976-) (orvos) Jambrik Zoltán Ruzsa Zoltán Lupkovics Géza Csanádi Zoltán (1960-) (kardiológus) Becker Dávid Merkely Béla (1965-) (orvos) Andréka Péter
Pályázati támogatás:EFOP-3.6.2-16-2017-00015
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM111209
035-os BibID:(scopus)85151758723
Első szerző:Papp Tímea Bianka (általános orvos)
Cím:Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation : Analysis of the Hungarian Health Insurance Fund Database / Papp Tímea, Kiss Zoltán, Rokszin György, Fábián Ibolya, Márk László, Bagoly Zsuzsa, Becker Dávid, Merkely Béla, Aradi Dániel, Dézsi Csaba András, Járai Zoltán, Csanádi Zoltán
Dátum:2023
ISSN:0149-2918
Megjegyzések:Purpose: Limited real-world data are available on the survival of patients treated with vitamin K antagonists (VKAs) versus with direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (AF). In this nationwide registry, we analyzed the mortality risk of patients with nonvalvular AF taking DOACs versus. VKAs, with a special attention to the early treatment period. Methods: The Hungarian National Health Insurance Fund (NHIF) database was searched to identify patients treated with VKA or DOAC as a thromboembolic prophylaxis for nonvalvular AF between 2011 and 2016. The overall and the early (0-3, 4-6, 7-12 months) mortality risks with the 2 types of anticoagulation were compared. A total of 144,394 patients with AF treated with either a VKA (n = 129,925) or a DOAC (n = 14,469) were enrolled. Findings: A 28% improvement in 3-year survival with DOAC treatment compared with VKA treatment was shown. Mortality reduction with DOACs was consistent across different subgroups. However, younger patients (30-59 years old) initiated on DOAC therapy had the greatest RRR (53%) in mortality. Furthermore, DOAC treatment also yielded a benefit of greater magnitude (HR 0.55; 95% CI, 0.40-0.77; p=0.001) in the lower (0-1) CHA2DS2-VASc score segment and in those with fewer (0-1) bleeding risk factors (HR: 0.50; 95% CI, 0.34-0.73; p=0.001). The RRR in mortality with DOACs was 33% within the first 3 months, and 6% in the second year. Implications: Thromboembolic prophylaxis with DOACs in this study yielded significantly lower mortality compared with VKA treatment in patients with nonvalvular AF. The largest benefit was shown in the early period after treatment initiation, as well as in younger patients, those with a lower CHA2DS2-VASc score, and those with fewer bleeding risk factors.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
atrial fibrillation
direct oral anticoagulant
mortality risk reduction
thromboembolism
vitamin K antagonist
Megjelenés:Clinical Therapeutics. - 45 : 4 (2023), p. 333-346. -
További szerzők:Kiss Zoltán (Pécs) Rokszin György Fábián Ibolya Márk László (1956-) (belgyógyász, kardiológus) Bagoly Zsuzsa (1978-) (orvos) Becker Dávid Merkely Béla (1965-) (orvos) Aradi Dániel Dézsi Csaba András Járai Zoltán Csanádi Zoltán (1960-) (kardiológus)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1